MA49042A - Polythérapies ciblant pd-1, tim-3 et lag-3 - Google Patents

Polythérapies ciblant pd-1, tim-3 et lag-3

Info

Publication number
MA49042A
MA49042A MA049042A MA49042A MA49042A MA 49042 A MA49042 A MA 49042A MA 049042 A MA049042 A MA 049042A MA 49042 A MA49042 A MA 49042A MA 49042 A MA49042 A MA 49042A
Authority
MA
Morocco
Prior art keywords
polytherapies
tim
lag
targeting
targeting polytherapies
Prior art date
Application number
MA049042A
Other languages
English (en)
Inventor
Camilla Fröhlich
Monika Gad
Michael Monrad Grandal
Ivan David Horak
Michael Kragh
Johan Lantto
Trine Lindsted
Eva Maria Carlsen Melander
Mikkel Wandahl Pedersen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MA49042A publication Critical patent/MA49042A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA049042A 2017-04-05 2018-04-05 Polythérapies ciblant pd-1, tim-3 et lag-3 MA49042A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762481973P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
MA49042A true MA49042A (fr) 2020-02-12

Family

ID=62027945

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049042A MA49042A (fr) 2017-04-05 2018-04-05 Polythérapies ciblant pd-1, tim-3 et lag-3

Country Status (21)

Country Link
US (3) US11939380B2 (fr)
EP (3) EP4230654A1 (fr)
JP (3) JP7832755B2 (fr)
KR (2) KR102737715B1 (fr)
CN (2) CN114984209B (fr)
AU (2) AU2018247916B2 (fr)
BR (1) BR112019020662A2 (fr)
CA (2) CA3185303A1 (fr)
CL (2) CL2019002850A1 (fr)
CO (1) CO2019012080A2 (fr)
EA (1) EA201992350A1 (fr)
IL (1) IL269644B2 (fr)
MA (1) MA49042A (fr)
MX (2) MX2019011961A (fr)
MY (1) MY204068A (fr)
PE (1) PE20191741A1 (fr)
PH (1) PH12019502191A1 (fr)
SG (2) SG11201908919XA (fr)
TW (2) TWI822101B (fr)
UA (1) UA129904C2 (fr)
WO (1) WO2018185232A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
WO2017055404A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps bispécifiques spécifiques de pd1 et tim3
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
PH12019500668B1 (en) 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
UA129904C2 (uk) * 2017-04-05 2025-09-10 Ле Лаборатуар Сервьє Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку
EP4516809A3 (fr) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Anticorps bispécifiques se liant spécifiquement à pd1 et lag3
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3737700A1 (fr) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Anticorps dirigés contre tim3 et leurs utilisations
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
EP3969040A1 (fr) * 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
CN112812179B (zh) * 2021-01-19 2022-07-22 北京大学 高亲和力高特异性抗cmtm6单克隆抗体及其用途
KR20250035054A (ko) * 2022-06-07 2025-03-11 인사이트 코포레이션 암을 치료하기 위한 항-pd-1 활성제, 항-tim-3 활성제, 및 항-lag-3 활성제의 조합 요법
WO2024041652A1 (fr) * 2022-08-25 2024-02-29 Beigene, Ltd. Méthodes de traitement du cancer
WO2024041651A1 (fr) * 2022-08-25 2024-02-29 Beigene, Ltd. Méthodes de traitement du cancer à l'aide d'anticorps anti-pd1 en combinaison avec des anticorps anti-tim3 et des anticorps anti-lag3
CN119789867A (zh) * 2022-09-06 2025-04-08 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN120752053A (zh) * 2023-03-03 2025-10-03 正大天晴药业集团南京顺欣制药有限公司 含抗tim-3抗体的药物组合
KR20250001490A (ko) * 2023-06-28 2025-01-07 주식회사 니오바이오파마슈티컬스 항-lag-3 항체, 항원 결합성 단편 및 이들의 용도
CN117159703B (zh) * 2023-11-02 2024-04-02 正大天晴(广州)医药有限公司 含抗lag-3抗体的药物组合物及其用途

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (fr) 1985-04-01 1995-04-26 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
CA2189657C (fr) 1994-05-06 2002-03-12 Florence Faure Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2054086A1 (fr) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG Conjugué d'un anticorps dirigé contre le ccr5 et peptide antifusiogène
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
MX2009012526A (es) 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009097394A2 (fr) 2008-01-29 2009-08-06 The Brigham And Women's Hospital, Inc. Procédés pour moduler une population de cellules myéloïdes suppressives et leurs utilisations
NZ588651A (en) 2008-04-23 2012-04-27 Symphogen As Methods for manufacturing a polyclonal protein
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
BRPI0920032A2 (pt) 2008-10-06 2017-06-27 Symphogen As método para identificar e selecionar candidatos a fármacos para produtos farmacológicos combinatórios
WO2010084999A1 (fr) 2009-01-26 2010-07-29 Protegene, Inc. Agents immunosuppresseurs et agents prophylactiques et thérapeutiques pour des maladies auto-immunes
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2011159877A2 (fr) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
WO2013164689A2 (fr) 2012-05-02 2013-11-07 Lantto, Johan Compositions d'anticorps pan-her humanisés
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
JP6595458B2 (ja) * 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CN103936853B (zh) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
CA2942245C (fr) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reduction des niveaux ou de l'activite systemiques des lymphocytes t regulateurs en vue du traitement de maladies et de lesions touchant le snc
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
ES2851451T3 (es) * 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
WO2016111947A2 (fr) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Anticorps inhibiteurs d'interactions de tim-3:lilrb2 et leurs utilisations
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
EP3265486A4 (fr) 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Anticorps thérapeutiques se liant à tim3
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
EP3337826A1 (fr) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anticorps anti-tim-3, compositions comprenant des anticorps anti-tim-3 et procédés de production et d'utilisation d'anticorps anti-tim-3
WO2017055404A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps bispécifiques spécifiques de pd1 et tim3
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
ES2924402T3 (es) 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
RS61510B1 (sr) * 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
PH12019500668B1 (en) 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
DK3541841T3 (da) 2016-11-18 2024-10-21 Servier Lab Anti-PD-1-antistoffer og sammensætninger
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
UA129904C2 (uk) 2017-04-05 2025-09-10 Ле Лаборатуар Сервьє Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
KR20220083863A (ko) 2022-06-20
TWI801376B (zh) 2023-05-11
JP7832755B2 (ja) 2026-03-18
EA201992350A1 (ru) 2020-03-23
TW201841652A (zh) 2018-12-01
MY204068A (en) 2024-08-06
JP7523491B2 (ja) 2024-07-26
RU2019134934A3 (fr) 2022-01-14
IL269644B2 (en) 2025-10-01
CN110621698B (zh) 2024-04-12
PE20191741A1 (es) 2019-12-12
SG11201908919XA (en) 2019-10-30
TW202235106A (zh) 2022-09-16
EP4230654A1 (fr) 2023-08-23
US11939380B2 (en) 2024-03-26
KR20190137105A (ko) 2019-12-10
CA3058960A1 (fr) 2018-10-11
SG10201912941PA (en) 2020-02-27
CN114984209B (zh) 2025-08-29
CA3185303A1 (fr) 2018-10-11
BR112019020662A2 (pt) 2020-05-05
US20240270848A1 (en) 2024-08-15
CN114984209A (zh) 2022-09-02
EP4116328A1 (fr) 2023-01-11
CO2019012080A2 (es) 2020-01-17
RU2019134934A (ru) 2021-05-05
KR102737715B1 (ko) 2024-12-03
PH12019502191A1 (en) 2020-06-15
IL269644B1 (en) 2025-06-01
AU2022204078A1 (en) 2022-06-30
CL2019002850A1 (es) 2020-03-13
CL2021003196A1 (es) 2022-09-23
JP2020513009A (ja) 2020-04-30
UA129904C2 (uk) 2025-09-10
MX2019011961A (es) 2019-12-05
MX2022007140A (es) 2022-07-19
US20220380470A1 (en) 2022-12-01
JP2022133296A (ja) 2022-09-13
JP2024023222A (ja) 2024-02-21
CN110621698A (zh) 2019-12-27
EP3606957A1 (fr) 2020-02-12
AU2018247916A1 (en) 2019-10-17
US20200407444A1 (en) 2020-12-31
CA3058960C (fr) 2023-08-29
IL269644A (en) 2019-11-28
WO2018185232A1 (fr) 2018-10-11
TWI822101B (zh) 2023-11-11
AU2018247916B2 (en) 2025-04-24
AU2022204078B2 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
MA49042A (fr) Polythérapies ciblant pd-1, tim-3 et lag-3
EP3664829A4 (fr) Agents de liaison à pd-1 et pd-l1
IL293377A (en) Hsd17b13 variants and uses thereof
IL272159A (en) Binding agents binding to pd-l1 and cd137 and use thereof
MA50147A (fr) Inhibiteurs de pd-1/pd-l1
HRP20260186T1 (hr) Inkretinski analozi i njihova upotreba
PL3370768T3 (pl) Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
IL259987A (en) Antibody molecules to pd-1 and uses thereof
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
PL3456346T3 (pl) Cząsteczki wiążące pd-1 i lag-3 oraz sposoby ich zastosowania
LT3472207T (lt) Surišančios molekulės, kurios suriša pd-l1 ir lag-3
HRP20251643T1 (hr) Anti‑par2 antitijela i njihove upotrebe
IL282178A (en) Products, uses & methods
HUE059788T2 (hu) PD-1 elleni antitestek és készítmények
PT3374291T (pt) Sistemas e métodos de colheita
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
DK3619201T3 (da) Herbicidvirksomme 4-difluormethylbenzoylamider
PL3135110T3 (pl) Pochodne 1,7-diarylo-1,6-heptadieno-3,5-dionu, sposób ich wytwarzania i ich zastosowanie
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
EP3706068A4 (fr) Système de détermination d'utilisation de terrain, procédé et programme de détermination d'utilisation de terrain
EP3699957A4 (fr) Module, et serveur
MA49905A (fr) Polyesteramines et polyesterquats